Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.85
Change (%) Stock is Up 0.05 (0.42%)
Volume74,889
Data as of 08/17/18 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
08/13/18Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
08/10/18Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
08/07/18Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
08/06/18Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
Upcoming EventsMore >>
DateTitle
09/04/18
through
09/06/18
Eiger BioPharmaceuticals at H.C. Wainwright 20th Annual Global Investment Conference
LocationNYC
09/04/18
Eiger BioPharmaceuticals at B. Riley FBR Healthcare Conference
LocationNYC
09/07/18
Eiger BioPharmaceuticals at BioCentury Newsmakers
LocationNYC
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.